RIFAXIMIN WITH STANDARD MEDICAL TREATMENT VERSUS STANDARD MEDICAL TREATMENT ALONE IN PATIENTS WITH FRAILTY IN DECOMPENSATED CIRRHOSIS - AN OPEN LABEL RANDOMISED TRIA

PGIMER0 个研究点目标入组 100 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•1. Patients with CTP score more than 10
•2. Patients with history of hepatic encephalopathy
•3. Patient with acute on chronic liver failure (ACLF)
•4. Obese patient (BMI;25kg/m2)
•5. Patients with active malignancy, hepatocellular carcinoma and end- stage renal disease
•6. Patients having prior study enrolment or enrolment in another conflicting study.
•7. Patients, who are not willing to participate in the study.
•8. Patients who are participating in other clinical trials within past 3 months.
•9. Patients who has an active evidence of infection
•10. Patients who had acute organic brain disease in the past 6 months
•11. Patients who has severe hemodynamic instability, serious heart disease, severe bradycardia or tachycardia at rest
•12. Patients having renal failure (creatinine clearance rate =60 mL/min/1.73 m2).
•13. Patients with severe cognitive impairment (Mini-Mental State Examination =17), overt hepatic encephalopathy or patients who had physical disability.
•14. Patients with HIV
•15. Pregnancy
•16. Post liver transplant patients
•17. Exposure to rifaximin in the previous 12 weeks
•18. Patients receiving concomitant secondary prophylaxis for SBP
•19. Known hypersensitivity to Rifaximin

发起方